Scott Merz, Business Development Manager at Asahi Kasei Bioprocess America, provides his take on the recent oligonucleotide manufacturing market growth, key considerations for development, and common challenges that arise when scaling up equipment.
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Please enter your email address and create a password to access the full content, Or
log in to your account to continue.
Please tell us more about you so that we can customize our newsletters to your specific interests: